Table 1 Patients characteristics
Case | Gender/age | NIH GVHD grade | Sites involved | Previous treatment | Time to diagnosis to ruxolitinib | Response obtained | Follow up (years) | Dose adjustments of ruxolitinib due to adverse events |
|---|---|---|---|---|---|---|---|---|
1 | Male/51 | 3 acute | Skin Lung | Tacrolimus Mycophenolate Corticosteroids Extracorporeal photopheresis | 21 days | Partial remission | 2 | No |
2 | Male/28 | 3 acute | Duodenal | Tacrolimus Mycophenolate Corticosteroids Extracorporeal photopheresis | 5 weeks | Complete remission | 2 | No |
3 | Male/56 | 3 acute | Skin | Cyclosporine Methotrexate Corticosteroids Extracorporeal photopheresis | 5 weeks | Complete remission | 1 | No |
4 | Female/26 | 3 chronic | Skin Oral mucosa Lung | Tacrolimus Mycophenolate Corticosteroids Extracorporeal photopheresis | 3 months | Partial remission | 1 | Yes 50% reduction for neutropenia grade 2 |
5 | Male/52 | 3 chronic | Skin Liver Oral mucosa | Tacrolimus Mycophenolate Corticosteroids Extracorporeal photopheresis | 3 months | Partial remission | 1 | No |
6 | Female/36 | 3 chronic | Skin | Cyclosporine Methotrexate Corticosteroids Extracorporeal photopheresis | 10 months | Partial remission | 1 | No |
7 | Male/46 | 3 chronic | Skin Liver | Cyclosporine Methotrexate Corticosteroids Imatinib Extracorporeal photopheresis | 18 months | Partial remission | 1 | No |
8 | Female/26 | 2 chronic | Lung | Tacrolimus Mycophenolate Corticosteroids Extracorporeal photopheresis | 6 months | Complete remission | 1 | Yes 75% reduction for neutropenia grade 2 |